Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis

Abstract

ICI therapy can be resumed in patients with melanoma who have recovered from grade 3 to 4 ICI hepatitis with a modest risk of serious irAEs. It remains unclear whether ICI retreatment improves clinical outcomes.